Larimar Therapeutics (LRMR) EPS (Basic) (2016 - 2020)
Historic EPS (Basic) for Larimar Therapeutics (LRMR) over the last 8 years, with Q1 2020 value amounting to -$0.59.
- Larimar Therapeutics' EPS (Basic) fell 6914.19% to -$0.59 in Q1 2020 from the same period last year, while for Sep 2020 it was -$0.68, marking a year-over-year increase of 9210.71%. This contributed to the annual value of -$7.46 for FY2019, which is 29254.75% down from last year.
- Larimar Therapeutics' EPS (Basic) amounted to -$0.59 in Q1 2020, which was down 6914.19% from -$1.2 recorded in Q4 2019.
- Larimar Therapeutics' 5-year EPS (Basic) high stood at -$0.35 for Q1 2019, and its period low was -$2.11 during Q3 2019.
- Moreover, its 5-year median value for EPS (Basic) was -$0.54 (2016), whereas its average is -$0.72.
- In the last 5 years, Larimar Therapeutics' EPS (Basic) surged by 5584.8% in 2016 and then tumbled by 41577.38% in 2019.
- Quarter analysis of 5 years shows Larimar Therapeutics' EPS (Basic) stood at -$0.38 in 2016, then fell by 24.73% to -$0.48 in 2017, then increased by 18.23% to -$0.39 in 2018, then crashed by 207.63% to -$1.2 in 2019, then skyrocketed by 50.66% to -$0.59 in 2020.
- Its EPS (Basic) was -$0.59 in Q1 2020, compared to -$1.2 in Q4 2019 and -$2.11 in Q3 2019.